Ngm Biopharmaceuticals Inc financial data

Industry
Pharmaceutical Preparations
Location
333 Oyster Point Boulevard, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2023 - Mar 11, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 718 % +4.45%
Debt-to-equity 14.9 % -10.8%
Return On Equity -77.9 % -37.4%
Return On Assets -67.8 % -39.6%
Operating Margin -3.43K % -1041%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 83.5M shares +1.34%
Common Stock, Shares, Outstanding 82.9M shares +1.25%
Entity Public Float 147M USD -79%
Common Stock, Value, Issued 83K USD +1.22%
Weighted Average Number of Shares Outstanding, Basic 82.5M shares +3.18%
Weighted Average Number of Shares Outstanding, Diluted 82.5M shares +3.18%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 4.42M USD -92%
Research and Development Expense 118M USD -34.8%
General and Administrative Expense 37.8M USD -6.6%
Operating Income (Loss) -151M USD +8.89%
Net Income (Loss) Attributable to Parent -142M USD +12.5%
Earnings Per Share, Basic -1.73 USD/shares +14.8%
Earnings Per Share, Diluted -1.73 USD/shares +14.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 55.8M USD -24%
Cash, Cash Equivalents, and Short-term Investments 144M USD -46.9%
Assets, Current 156M USD -45.8%
Property, Plant and Equipment, Net 7.03M USD -17.2%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 2.94M USD -26.5%
Assets 169M USD -45.1%
Accounts Payable, Current 2.98M USD -64.7%
Employee-related Liabilities, Current 9.61M USD
Accrued Liabilities, Current 17.1M USD -49.2%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 20.1M USD -58%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 149K USD
Liabilities 20.2M USD -57.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 18K USD
Retained Earnings (Accumulated Deficit) -724M USD -24.5%
Stockholders' Equity Attributable to Parent 149M USD -42.7%
Liabilities and Equity 169M USD -45.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -41.8M USD -17%
Net Cash Provided by (Used in) Financing Activities 279K USD -58.2%
Net Cash Provided by (Used in) Investing Activities 35.6M USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 82.9M shares +1.25%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.91M USD +85.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 61.3M USD -20.9%
Deferred Tax Assets, Valuation Allowance 144M USD +22.2%
Deferred Tax Assets, Gross 144M USD +21.3%
Operating Lease, Liability 1.38M USD
Depreciation 2.22M USD -45%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -142M USD +12.8%
Lessee, Operating Lease, Liability, to be Paid 1.38M USD
Property, Plant and Equipment, Gross 51.9M USD +0.94%
Operating Lease, Liability, Current 0 USD -100%
Operating Lease, Weighted Average Discount Rate, Percent 0.03 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3K USD
Deferred Tax Assets, Operating Loss Carryforwards 85.3M USD +9.99%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 54.2M USD +40.1%
Operating Lease, Payments 1.3M USD 0%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%